While MASLD reclassifies NAFLD with a focus on metabolic drivers, the therapeutic interventions studied, such as GLP-1 agonists and Resmetirom, target shared underlying mechanisms, including insulin resistance, lipid metabolism, and inflammation. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.